Role of cytokines in experimental and human visceral leishmaniasis

M Samant, U Sahu, SC Pandey… - Frontiers in cellular and …, 2021 - frontiersin.org
Visceral Leishmaniasis (VL) is the most fatal form of disease leishmaniasis. To date, there
are no effective prophylactic measures and therapeutics available against VL. Recently, new …

Animal models for the study of leishmaniasis immunology

EN Loría-Cervera, FJ Andrade-Narváez - Revista do Instituto de …, 2014 - SciELO Brasil
Leishmaniasis remains a major public health problem worldwide and is classified as
Category I by the TDR/WHO, mainly due to the absence of control. Many experimental …

Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach

N Khatoon, RK Pandey, VK Prajapati - Scientific reports, 2017 - nature.com
Visceral leishmaniasis (VL) is a fatal form of leishmaniasis which affects 70 countries,
worldwide. Increasing drug resistance, HIV co-infection, and poor health system require …

Vaccine candidates for leishmaniasis: a review

R Nagill, S Kaur - International immunopharmacology, 2011 - Elsevier
Leishmaniasis is a diverse group of clinical syndromes caused by protozoan parasites of the
genus Leishmania. The clinical manifestation of the disease varies from self-limiting …

Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis

A Khamesipour, Y Dowlati, A Asilian… - Vaccine, 2005 - Elsevier
To establish the safety and reproducibility of live challenge with Leishmania major, a single
frozen stabilate was used in two open, single-arm leishmanization (LZ) trials. A total of 42 …

[PDF][PDF] Leishmaniasis vaccine candidates for development: a global overview

A Khamesipour, S Rafati, N Davoudi… - Indian Journal of …, 2006 - academia.edu
A vaccine against different forms of leishmaniasis should be feasible considering the wealth
of information on genetics and biology of the parasite, clinical and experimental immunology …

Leishmania vaccines: progress and problems

L Kedzierski, Y Zhu, E Handman - Parasitology, 2006 - cambridge.org
Leishmania are protozoan parasites spread by a sandfly insect vector and causing a
spectrum of diseases collectively known as leishmaniasis. The disease is a significant …

Visceral leishmaniasis: experimental models for drug discovery

S Gupta - Indian Journal of Medical Research, 2011 - journals.lww.com
Visceral leishmaniasis (VL) or kala-azar is a chronic protozoan infection in humans
associated with significant global morbidity and mortality. The causative agent is a …

Animal models for vaccine studies for visceral leishmaniasis

R Garg, A Dube - Indian Journal of Medical Research, 2006 - repository.ias.ac.in
Visceral leishmaniases (VL) or kala-azar is the most dreaded and devastating amongst the
various forms of leishmaniases. The disease, though localized in certain areas only, has …

[HTML][HTML] The diverse applications of recombinant BCG-based vaccines to target infectious diseases other than tuberculosis: an overview

E Mouhoub, P Domenech, M Ndao… - Frontiers in …, 2021 - frontiersin.org
Live attenuated Bacillus Calmette-Guérin (BCG) is the world's most widely used vaccine
which is mainly administered for its protection against tuberculosis (TB), particularly in young …